Zonisamide Product not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
- Main trialPhase 4
- “The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures. The study consists of four periods: a Screening Period (about 14 days), a Titration Period (8 weeks), a Maintenance Period (4 weeks), and a Follow-Up Period (1 week).”In the company’s words, NCT06534502 on ClinicalTrials.gov
- Other names
- ZONISADE · Zonisamide oral suspension
Other drugs for Seizures
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- EverolimusNovartis · Phase 3
- CarisbamateSK Life Science, Inc. · Phase 3
- Clemizole HClEpygenix · Phase 3
Coming up1
- Sep 2027Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | Sep 2027 | Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026